Philips to Introduce Latest Advancements In Digital Pathology at the European Congress of Pathology 2020 Virtual Event

December 4, 2020

Philips will introduce their latest advancements in digital pathology at the European Congress of Pathology 2020 virtual event, Dec. 6-8. Building on its strong portfolio to support oncology clinical decision-making, the company brings together the power of imaging, pathology, genomics, and longitudinal data with insights from artificial intelligence, to empower clinicians to deliver clear care pathways with predictable outcomes for every patient.

Pathology is vital to healthcare delivery, with 70% of decisions affecting a person’s life involving a laboratory or pathology test [1]. However, with current resource shortages, the growing volume of complex requests, and workflow inefficiencies across systems and departments, pathology labs are facing major pressures on multiple fronts.

Rather than viewing oncology as many single moments of care, Philips envisions a continuous care pathway empowered by integrated solutions for oncology and pathology that help transform and enhance multi-disciplinary workflows, including the oncology tumor board process. Critical patient data is made visible for both oncologists and pathologists, which allows them to collaborate more efficiently, to drive the right care in the right sequence at the right time.

By taking a systems view across the imaging enterprise, Philips leverages the power of smart diagnostic technologies and advanced informatics to remove the obstacles standing in the way of optimized workflows. The newly released Philips IntelliSite Pathology Solution features a leading-edge user experience (UX), enhancing the ease of use while helping streamline the imaging workflow in an automated digital solution. With this latest iteration, the company connects healthcare systems to scale digital operations and improve efficiency in high volume scanning, stimulate collaboration, and enable precision diagnosis.

Philips IntelliSite Pathology Solution offers an open, scalable, and interoperable platform that supports flexibility in deployments of image analysis software tools, strengthening Philips’s commitment to the Open Pathology platform. Other software tools allow developers and researchers to work with data natively in the iSyntax format for core research and algorithm development, enabling collaboration for education and the creation of third-party applications.

“A precise diagnosis informs the patient’s care pathway progress, from screening and diagnosis to treatment, monitoring, assessment, and the transition toward home care,” said Kees Wesdorp, Chief Business Leader Precision Diagnosis at Philips. ”Philips integrated solutions for oncology, including this latest enhancement in digital pathology, help empower the cancer care team to reach clinical treatment decisions based on richer dashboards, clinical images, reports, and structured patient data. The seamless integration of information into the oncology workflow will help improve the clinician experience and ultimately, patient outcomes.”

[1] Report of the Second Phase of the Review of NHS Pathology Services in England, Lord Carter of Coles.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.